<DOC>
	<DOCNO>NCT00294931</DOCNO>
	<brief_summary>This multicenter phase II trial design study unique combination chemotherapy ( irinotecan./carboplatin ) bevacizumab extensive-stage setting . This clinical setting seem ideal evaluation role bevacizumab delay progression prolong survival .</brief_summary>
	<brief_title>Irinotecan , Carboplatin , Bevacizumab Treatment Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Eligible patient receive 6 course irinotecan , carboplatin , bevacizumab . The interval chemotherapy course 28 day . If 6 course treatment , patient 's response CR/PR/SD continue Bevacizumab tumor progression 6 cycle ( 6 month ) total . Treatment sequence : - Irinotecan 60mg/m2 day 1 , 8 , 15 - Carboplatin AUC=4 day 1 - Bevacizumab 10 mg/kg day 1 15</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm small cell lung cancer , extensive stage disease . Measurable evaluable disease No previous chemotherapy Able perform activity daily live minimal assistance Adequate hematological , live kidney function Provide write informed consent Limited stage disease PEG G tube Hemoptysis Abdominal fistula , perforation , abscess within previous 6 month Women pregnant lactate Proteinuria Serious nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Uncontrolled serious cardiovascular disease Uncontrolled brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day ; Fine needle aspiration within 7 day Patients require fulldose anticoagulation must stable dose schedule prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Lung Cancer , Small Cell</keyword>
	<keyword>Extensive</keyword>
</DOC>